350 results about "Magnolol" patented technology

An efficacious antibacterial and anti-inflammatory oral composition is provided having an active ingredient combination comprising one or more active compounds from an extract of magnolia and an extract of hops. Preferably, the active compounds from magnolia extract comprise honokiol and magnolol, and the active compounds from hops extract comprise hexahydrogenated beta acids. The oral composition can be in the form of a mouth rinse or dentifrice, including toothpaste, gels, powders, confectionaries, lozenges, animal products, and the like. Methods of making and using the oral composition are also provided.

The invention provides methods for treating medical conditions caused by abnormal chloride ion flux with compositions containing active ingredients isolated from the traditional Chinese medicine Bao-Ji-Wan (BJW). The compositions comprise any one, two, or three of the following: magnolol, honokiol, imperatorin, isoimperatorin or only magnolol, honokiol, imperatorin, isoimperatorin and a physiologically acceptable carrier. In preferred embodiments, the medical conditions include disorders of the gastrointestinal tract, such as diarrhea and constipation.

The application of Magnolia officinalis preparation for the production of medicaments for treating diabetes and obesity belongs to the field of medicinal application. The Magnolia officinalis preparation is extracted from Magnolia officinalis by soaking in ethanol with magnolol and honokiol as main ingredients. The preparation has effects of in-vitro inhibiting the activity of protein-tyrosine phosphatase 1B (PTP1B) and reducing blood sugar level in rat model of type 2 diabetes. The preparation can be made into powder, pill, capsule, tablet, oral liquid and injection. It can be used for treating diabetes, obesity, and diseases related to PTP1B.

The invention discloses a method for extracting magnolol and honokiol crude extract with high efficiency, the method is that: the magnolol is dried up and crushed and sieved into 30 mesh, the magnolol is added to edible alcohol twice at the weight proportion of one grams of magnolol powder to 12 to 20ml edible alcohol, the extract temperature is 80 to 90 DEGC, the extract time is 2.0 to 3.0 hours each time, the concentration of edible alcohol is 50 to 70 percent, the two extraction crude filter liquors are combined and sieved into 200-mesh nylon fabric, a high speed centrifuge is used for centrifuging and clarifying and a clear liquid is taken out; the clear liquid at the temperature of 40 to 45 DEG C is carried out vacuum concentration by a rotary evaporator, the edible alcohol solvent is recovered and is frozen and dried in vacuum so as to obtain the crude extract, the extract rate of magnolol and honokiol is obviously higher than that of the prior art, the amounted manufacturing cost is relatively low. The method is harmless to the human body as well as to the environment by adopting edible alcohol for extraction; therefore, the method is particularly safe.

Provided are compositions, comprising a neolignan, ectoin, and a molecule of Formula I:

The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided.

The invention discloses a method for preparing high-purity magnolol and magnolol. The method comprises the following steps: preparing a Magnolia officinalis bark extract by use of a weakly polar solvent under heating condition, concentrating the extract, and adopting an ethanol water precipitation method to remove partial impurities; filtering, concentrating the filtrate under reduced pressure to obtain magnolol and magnolol extractum; standing the extractum to separate out the precipitate, dissolving with a small amount of petroleum ether, filtering, washing with petroleum ether, and precipitating to obtain a solid material which is crude magnolol; and then performing selective extraction with a solvent to separately obtain magnolol and crude magnolol, and recrystallizing the crude magnolol to obtain high-purity magnolol and magnolol respectively. The technology of the method has the advantages of fewer production steps, simple equipment and operation method, short production cycle and high product yield and purity; and the method is suitable for industrial production.

A freeze-dried powder of honokiol liposome for preparing the medicines to treat lung cancer and mammary cancer is proportionally prepared from honokiol, polyethanediol-phosphatidylethanolamine, lecithin and cholesterol. It has high synergistic and sensitizing action when it is applied in conjunction with chemicotherapeutic medicine.

The invention discloses a method for extracting honokiol and magnolol from a mangnolia officinalis crude extract. In existing methods of separating the honokiol from the magnolol in the mangnolia officinalis crude extract, in some methods, the cost is too high, the production volume is low, and mass production is not easy to achieve. In the method disclosed by the invention, by means of the characteristic that the magnolol and the honokiol contained in the mangnolia officinalis crude extract can be completely separated in a weak polar solution under an alkaline condition with certain concentration, the magnolol is extracted from a mixed solution by using a weak alkaline solvent, the honokiol is left in the solution, the honokiol is extracted by a strong alkaline solution, some oily impurities are left in an organic solvent layer, then acid regulation and precipitate out are carried out respectively, at this time, the contents of the honokiol and the magnolol in the obtained coarse-grain are greatly improved. The method disclosed by the invention is simple and feasible in separation and purification process and is suitable for large-scale industrial production, and the prepared magnolol and honokiol can be used for developing new medicines with single components.

The invention provides a preparation method of stomachic pill with cyperus and amomum, including following steps: banksian rose, amomum fruit, astraolylis lancea formalyrata, dried old orange peel, tuckahoe, pinellia(processed), autgrass galingale rhizome(processed with vinegar), fruit of immature citron(sauted), round cardamom(decladded), bark of official magnolia( baked with ginger),patchouli and liquorice are respectively pulverized and mixed at first, then through the steps such as adding adhesive, granulating, drying, finishing granule, pelleting and lagging cover orderly, the product can be obtained; the adhesive is decoction solution of ginger and jujube. The preparation method has the advantages of simple technology and convenient operation, moreover, the finished product has steady quality, and compared with the former stomachic pill with cyperus and amomum, the stomachic pill with cyperus and amomum can shorten dissolving time by over 70 to 90 percent, thereby the medicine can be absorbed faster, and the contents of magnolol and honokiol are higher, thus solving the problem of nonuniform size of the pellet prepared by the water-pill method, and the dosage of the medicine can be more exact; at the same time, the invention also increases rate of finished products at one time.

The invention relates to the technical field of chemicals for daily use, and particularly relates to a formula of plant active liquid shampoo and a preparation method thereof. The formula of the plant active liquid shampoo comprises the following components in percentage by weight: 1.0-15.0% of sapindus-saponin, 1.0-20.0% of tea saponin, 3.0-20.0% of sodium lauroyl glutamate, 3.0-30.0% of cocamidopropyl betaine, 0.1-2.0% of glutamic acid, 0.1-2.0% of menthol, 0.5-5.0% of glycerin, 0.2-2.0% of vitamin E, 0.2-2.0% of vitamin H, 0.1%-1.0% of baicalin, 0.1%-1.0% of cnidium lactone, 0.1%-2.0% of magnolol, 0.5-2.0% of ethyleneglycol monostearate, 0.2-2.0% of potassium sorbate, 0.1-0.5% of D-sodium erythorbate, 0.3-5.0% of quaternary ammoniated B5, 0.1%-0.5% of citric acid, 0.1%-2.0% of ginger oil, 0.5-5.0% of guar hydroxypropyltrimonium chloride, 0.3-5.0% of food-grade PAM, 0.1%-3.0% of NaCL and the balance of deionized water. A surface active agent and a bactericide of the formula of the plant active liquid shampoo adopt plant activity and biological agents, and therefore, the plant active liquid shampoo is suitable for all types of people, especially pregnant women and infants.

The invention belongs to the technical field of stem cells and relates to a serum-free medium for placenta-derived mesenchymal stem cells and a preparation method thereof. The serum-free medium comprises a DMEM basic medium and further comprises vitamin H, glutathione, recombinant human insulin, human serum albumin, transferrin, fibroblast growth factors, epidermal growth factors, stem cell growth factors, Human stem cell factors and magnolol. The serum-free medium provided by the invention has the advantages of high safety and capability for significant improvement of proliferative capability of placenta-derived mesenchymal stem cells, the serum-free medium is capable of well keeping cell forms and stem cell characteristics of the placenta-derived mesenchymal stem cells and is convenient to popularize and apply.

The invention discloses a method for extracting magnolol from officinal magnolia barks. The method comprises the following steps of raw material processing, high-pressure microjet superfine smashing processing, supersonic extraction, extraction, crystallization and drying to obtain the magnolol, and has the advantages of being high in content, high in extraction rate, simple in process, suitable for production, low in production cost and the like.

The invention relates to a honokiol or magnolol or honokiol-magnolol mixed solid lipid nanosphere preparation and a preparation method thereof. According to the invention, the production problem of the honokiol or magnolol or honokiol-magnolol mixed solid lipid nanosphere preparation can be effectively solved. The raw materials of the honokiol or magnolol or honokiol-magnolol mixed solid lipid nanosphere preparation comprise 0.001-40 wt% of honokiol or magnolol or the honokiol-magnolol mixture, 0.05-99.9 wt% of the solid lipid material, 0.001-85 wt% of a surfactant, and the balance being disperse medium, wherein the sum of the weight of honokiol or magnolol or the honokiol-magnolol mixture, the solid lipid material and the surfactant accounts for 0.01-60% of the total weight of the lipid nanosphere preparation. The preparation method provided by the invention comprises the following steps of: preparing a dispersed phase, preparing a continuous phase, mixing the dispersed phase and the continuous phase, dispersing the mixture to a nanometer preparation, filtering and sterilizing. The honokiol or magnolol or honokiol-magnolol mixed solid lipid nanosphere preparation has advantages of scientific composition, simple preparation and good stability, can be prepared in the forms of an injection and an ophthalmic preparation, or processed in the forms of a solid preparation, a semisolid preparation and a gas preparation.

The invention relates to compound medicine mouth wash. The compound medicine mouth wash takes deionized water as a main component, and is at least added with a composition of tranexamic acid, chlorogenic acid, baicalin and forsythiaside. According to the compound medicine mouth wash, a way that the chlorogenic acid, baicalin and forsythiaside are combined with the tranexamic acid for use is adopted, so that the aims of quickly preventing gingival bleeding, effectively inhibiting oral bacteria, and treating both symptoms and root causes can be realized; meanwhile, introduced L-zinc lactate and magnolol can produce a synergism effect with the formula, and anti-microbial and hemostatic effects of the mouth wash are further improved.

The invention belongs to the field of medicine, and particularly relates to magnolol liposome and a derivative preparation and a preparation method thereof. The liposome prepared by taking magnolol as an active ingredient is capable of improving storage stability of pharmaceutic preparations as well as allowing drugs in the liposome to release sustainably. The magnolol liposome comprises, by weight, 1 part of magnolol, 2.5-11 parts of phospholipid, 0.4-3 parts of cholesterol and 0.10-3 parts of hydrophilic lipid derivatives. The preparation method of the liposome is simple and easy to implement, and the liposome is controllable in quality and convenient for industrial production; the magnolol liposome is small in particle size, uniform in distribution and high in entrapment efficiency, storage stability of the pharmaceutic preparations can be improved, the drugs in the liposome are allowed to release sustainably, retention time of the drugs in blood circulation is prolonged, bioavailability of the drugs is heightened, and the high-efficiency long-acting treatment goal is met.

The invention provides a method for separating and purifying magnolol and honokiol by HP-20 macroporous resin. The method comprises a step of extracting coarse extracts of magnolia bark by 50 to 70 volume percent edible ethanol at the temperature of between 80 and 90 DEG C; and the method also comprises a step of separating and purifying the coarse extracts of magnolia bark by the HP-20 macroporous adsorptive resin, in which the coarse extracts of magnolia bark is dissolved in the edible ethanol, the HP-20 macroporous adsorptive resin is used for adsorption until saturated, the coarse extracts of magnolia bark are eluted by water, low-concentration edible ethanol and high-concentration edible ethanol respectively, the eluent is collected in order, the collected eluent is condensed by decompression to recover the ethanol, and then freeze-dried under a vacuum condition to obtain the purified magnolol and honokiol. By adopting the method, the magnolol and honokiol can be safely and effectively separated and purified by industrialized production.

The invention discloses a novel application of honokiol and fluconazole in antifungal cooperation. According to the invention, the fungi are candida albicans. According to the invention, a standard macrodilution drug sensitivity experiment recommended by CLSI is adopted, in vitro sensitivity of honokiol towards clinically separated drug resistant candida albicans is evaluated with systematic methods such as a checkerboard macrodilution method and a time-kill curve method. Also, an in vitro synergistic effect of honokiol and fluconazole in clinic drug resistant fungi resistance is evaluated. Further, with a mice infection and treatment experiment, an in vivo synergistic effect of honokiol and fluconazole in clinic drug resistant fungi resistance is evaluated.

The invention discloses a preparation method for a magnolol molecularly imprinted polymer film. The preparation method includes the following concrete steps: both imprinted molecule magnolol and solid-phase reagent are put into a ball mill and ball-milled, so that imprinted molecule inclusion compound is obtained, and the inclusion compound, functional monomer, cross-linking agent and initiator are put into porogen, ultrasonically degasified, then added with bond and ultrasonically stirred, so that mixture is obtained; filter paper is immersed in the mixture, taken out, clamped between two glass sheets, put into an oven and heated to be polymerized, so that polymer is obtained; imprinted molecules are removed from the obtained polymer, and after washing and drying, the magnolol molecularly imprinted polymer film is obtained. The preparation method adopts the mechanochemical technology to include the imprinted molecules, so that the ability of the imprinted molecules in specific binding with the functional monomer is enhanced, as a result, the recognition selectivity of the finally prepared molecularly imprinted polymer film is greatly enhanced, and the magnolol separation effect is good.

The invention relates to an anti-inflammatory and antibacterial mouthwash, which uses deionized water as the main component and at least adds a combination of magnolol, wild chrysanthemum extract, andrographis paniculata extract and honeysuckle extract. In this case, the combined use of magnolol, wild chrysanthemum extract, andrographis paniculata extract and honeysuckle extract can quickly reduce inflammation, prevent bleeding gums, effectively inhibit oral bacteria, and achieve the goal of treating both symptoms and root causes.

The invention discloses an application of magnolol in killing fish parasitic protozoa and a preparation thereof. As a pollution-free green novel fish drug, the magnolol brings low toxicity to fish, rarely generates drug resistance and can effectively kill in-vitro and in-vivo ichthyophthirius multifilis; the magnolol, ethanol and rapeseed oil are mixed and stirred until the magnolol is completely dissolved to obtain a mixed solution; a surfactant and a transdermal agent are added into the mixed solution; and then the mixture is stirred uniformly to obtain a control agent for killing fish parasitic protozoa, wherein the magnolol accounts for 6-12%, the ethanol accounts for 3-6%, the surfactant accounts for 1-3%, the transdermal agent accounts for 1-4% and the balance is the rapeseed oil. The production cost of the control agent is low, the application method is simple, and the promotion and application are promoted.

The invention relates to a detection method of a medicinal preparation of cortex magnoliae officinalis seven-object soup. According to the method, by optimizing an extraction solvent, extraction time and an extraction method, various chemical components in the medicinal preparation of the cortex magnoliae officinalis seven-object soup are furthest extracted; by optimizing an chromatographic column, a mobile phase and an elution mode of the mobile phase, the various chemical components are better separated; thus a method for a fingerprint spectrum of the medicinal preparation is established, and relatively comprehensive spectrum information is acquired; further, by optimally selecting No.8 peak naringin as an internal reference peak, the facts that in common characteristic peaks, a No.9 peak is neohesperidin, a No.14 peak is ammonium glycyrrhetate, a No.15 peak is aloe-emodin, a No.17 peak is rhein, a No.18 peak is emodin, a No.19 peak is honokiol and a No.21 peak is magnolol are affirmed, and relative retention time of 21 common characteristic peaks is determined; by combining information of multiple chromatography peaks in the fingerprint spectrum, the quality can be comprehensively and systematically detected.